- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07944066
SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis (SAVE-AS)
Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Assess the Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitor in Patients With Aortic Valve Stenosis: SAVE-AS (SGLT2i Assessment Valvular Effect in AS)
Aortic stenosis (AS) is the most common valvular heart disease, and no medical therapy has been shown to slow its progression; treatment is limited to surgical or transcatheter aortic valve replacement once symptoms or left ventricular dysfunction develop. Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce cardiovascular death and heart failure hospitalization in patients with and without diabetes, and preclinical studies show that they suppress the inflammatory (NLRP3 inflammasome), fibrotic (TGF-beta/Smad), and oxidative-stress pathways that drive valve calcification. A recent observational study reported slower AS progression in patients treated with SGLT2 inhibitors.
SAVE-AS is a multicenter, prospective, randomized, double-blind, placebo-controlled, investigator-initiated superiority trial testing whether the SGLT2 inhibitor enavogliflozin (0.3 mg once daily) reduces the composite of all-cause death, aortic valve replacement, and hospitalization for heart failure in adults with asymptomatic moderate or severe aortic stenosis and preserved left ventricular ejection fraction (50% or higher). A total of 1,182 participants at 11 centers in the Republic of Korea will be randomized 1:1 to enavogliflozin or matching placebo, stratified by participating center and AS severity (moderate vs severe). Study treatment is given for 24 months, with follow-up visits at 2, 6, 12, 18, and 24 months and an end-of-treatment assessment at 25 months. Secondary outcomes include the individual components of the primary composite, cardiac death, echocardiographic AS severity, left ventricular mass, global longitudinal strain and ejection fraction, NT-proBNP, annual eGFR slope, and SGLT2 inhibitor-related adverse events. All clinical events are adjudicated by an independent clinical event adjudication committee, and safety is overseen by an independent data and safety monitoring board.
연구 개요
상세 설명
Design: Prospective, multicenter (11 sites, Republic of Korea), randomized (1:1), double-blind, placebo-controlled, parallel-group, superiority, investigator-initiated trial. Randomization is performed centrally through an interactive web response system (IWRS) managed by an independent organization, stratified by participating center and baseline AS severity (moderate vs severe).
Population: Adults aged 19 years or older with asymptomatic (NYHA class I) moderate or severe aortic stenosis, defined as aortic valve area less than 1.5 cm2, peak aortic jet velocity 3 m/s or higher, or mean pressure gradient 25 mmHg or higher, with left ventricular ejection fraction 50% or higher. Patients meeting ACC/AHA or ESC/EACTS indications for aortic valve intervention, with very severe AS (peak velocity 5 m/s or higher or mean gradient 50 mmHg or higher), severe concomitant valve disease, eGFR below 30 mL/min/1.73 m2 or dialysis, type 1 diabetes, or SGLT2 inhibitor use within 3 months are excluded.
Intervention: Enavogliflozin 0.3 mg orally once daily or matching placebo for 24 months, on top of guideline-directed medical therapy per ACC/AHA/SCAI or ESC/EACTS recommendations. Concomitant medications may be adjusted at the investigator's discretion.
Schedule: Screening (day -90 to 0), baseline/randomization (day 0), visits at day 60 +/- 30, 180 +/- 30, 360 +/- 30, 540 +/- 30, and 720 +/- 30, and end-of-treatment assessment at day 750 +/- 90. Transthoracic echocardiography is performed at baseline, 12, and 24 months (and at 6 and 18 months in participants with severe AS at baseline). Laboratory tests (including eGFR), NT-proBNP and cardiac troponin T, ECG, and chest radiography are obtained at prespecified visits. Medication adherence is assessed at every visit. Clinical events are ascertained at each follow-up visit and at the end-of-treatment assessment at 25 months, and thereafter vital status and clinical events are ascertained by visit, telephone contact, or medical-record review until the end of study.
Sample size: Assuming an annual primary-event rate of 6% in the placebo group, a hazard ratio of 0.65, 3 years of accrual, 2 additional years of follow-up, 5% dropout, two-sided alpha of 0.05, and 80% power, 591 participants per group (1,182 total) are required (time-to-event analysis, log-rank test).
Analysis: Primary analysis by intention to treat; per-protocol analysis (adherence 70% or higher, no SGLT2 inhibitor use in the placebo group) as sensitivity analysis. Time-to-event outcomes are analyzed by Kaplan-Meier estimates, log-rank test, and Cox proportional-hazards models; continuous echocardiographic and laboratory outcomes by independent t-test. Participants lost to follow-up are censored. Prespecified subgroups: AS severity (moderate vs severe), age (below 70 vs 70 years or older), diabetes, hypertension, chronic kidney disease, and baseline global longitudinal strain. An interim analysis is planned when approximately 50% of the expected data have been collected, reviewed by the independent data and safety monitoring board.
Oversight: All primary and secondary clinical events are adjudicated by an independent Clinical Event Adjudication Committee. An independent Data and Safety Monitoring Board reviews all serious adverse events. Serious adverse events are reported to the principal investigator within 72 hours and to each site IRB per local requirements. The trial is conducted in accordance with the Declaration of Helsinki, ICH-GCP, and Korean GCP (KGCP).
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 연락처
- 이름: GaHee Lee
- 전화번호: +82-2-2008-4135
- 이메일: gahee2.lee@sbri.co.kr
연구 연락처 백업
- 이름: Jinseon Heo
- 이메일: jinseon.heo@sbri.co.kr
연구 장소
-
-
-
Busan, 대한민국
- 아직 모집하지 않음
- Dong-A University Hospital
-
수석 연구원:
- Kyung Hee Lim, MD, PhD
-
Changwon, 대한민국
- 아직 모집하지 않음
- Samsung Changwon Hospital
-
수석 연구원:
- Mirae Lee, MD, PhD
-
Cheonan, 대한민국
- 아직 모집하지 않음
- Dankook University Hospital
-
수석 연구원:
- Su Yeon Lee, MD, PhD
-
Gwangmyeong, 대한민국
- 아직 모집하지 않음
- Chung-Ang University Gwangmyeong Hospital
-
수석 연구원:
- Eun Jeong Cho, MD, PhD
-
Seongnam, 대한민국
- 아직 모집하지 않음
- Seoul National University Bundang Hospital
-
수석 연구원:
- Jiesuck Park, MD, PhD
-
Seoul, 대한민국, 06351
- 모병
- Samsung Medical Center
-
연락하다:
- GaHee Lee
- 전화번호: +82-2-2008-4135
- 이메일: gahee2.lee@sbri.co.kr
-
수석 연구원:
- Sung-Ji Park, MD, PhD
-
Seoul, 대한민국
- 아직 모집하지 않음
- Korea University Anam Hospital
-
수석 연구원:
- So Ree Kim, MD, PhD
-
Seoul, 대한민국
- 아직 모집하지 않음
- Kangbuk Samsung Hospital
-
수석 연구원:
- Jiwon Kim, MD, PhD
-
Seoul, 대한민국
- 아직 모집하지 않음
- Konkuk University Medical Center
-
수석 연구원:
- Sung Hea Kim, MD, PhD
-
Seoul, 대한민국
- 아직 모집하지 않음
- Asan Medical Center, University of Ulsan College of Medicine
-
수석 연구원:
- Dae-Hee Kim, MD, PhD
-
Seoul, 대한민국
- 아직 모집하지 않음
- Severance Hospital, Yonsei University College of Medicine
-
수석 연구원:
- Chi Young Shim, MD, PhD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Able to understand the study protocol and provide written informed consent
- Adults aged 19 years or older
- Moderate or asymptomatic severe aortic stenosis, defined as all of the following:
- Aortic valve area (AVA) less than 1.5 cm2, aortic valve peak velocity (Vmax) 3 m/s or higher, or aortic valve mean pressure gradient 25 mmHg or higher
- Left ventricular ejection fraction 50% or higher
- Asymptomatic, New York Heart Association (NYHA) functional class I
Exclusion Criteria:
- Left ventricular ejection fraction below 50%
- Indication for aortic valve intervention according to current ACC/AHA or ESC/EACTS guidelines
- Symptomatic severe aortic stenosis
- Severe stenosis or regurgitation of another valve, or concomitant severe aortic regurgitation
- Very severe aortic stenosis (aortic valve Vmax 5 m/s or higher, or mean pressure gradient 50 mmHg or higher)
- NYHA functional class II to IV
- Use of an SGLT2 inhibitor within the previous 3 months
- Known hypersensitivity to SGLT2 inhibitors
- Estimated glomerular filtration rate below 30 mL/min/1.73 m2, or on dialysis
- Type 1 diabetes mellitus
- Pregnancy or breastfeeding
- Liver disease with AST or ALT 2 or more times the upper limit of normal, or history of hepatic encephalopathy, esophageal varices, or portosystemic shunt
- Life expectancy below 2 years, or inability to comply with the study protocol
- Diabetic ketoacidosis
- Current use of medications that may affect efficacy assessment (DPP-4 inhibitors, vitamin K, calcium supplements)
- Sexually active women of childbearing potential who do not agree to use adequate contraception during the study
- Participation in another clinical trial within the previous 1 month or 5 half-lives of the investigational product
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Enavogliflozin
Enavogliflozin 0.3 mg film-coated tablet orally once daily for 24 months, in addition to guideline-directed medical therapy. |
Sodium-glucose cotransporter-2 inhibitor, 0.3 mg film-coated tablet, taken orally once daily for 24 months.
다른 이름들:
|
|
위약 비교기: Placebo
Matching placebo tablet (identical in appearance) orally once daily for 24 months, in addition to guideline-directed medical therapy. |
Matching placebo tablet identical in appearance to enavogliflozin, taken orally once daily for 24 months. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Composite of all-cause death, aortic valve replacement, or hospitalization for heart failure
기간: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Time to first occurrence of any component of the composite: all-cause death; surgical or transcatheter aortic valve replacement; or hospitalization for heart failure, defined as presentation to an acute care facility requiring an overnight stay with symptoms and signs of heart failure and treatment with intravenous diuretics, vasodilators, or inotropes, mechanical fluid removal, intra-aortic balloon pump, or initiation/doubling of oral diuretics. All events are adjudicated by an independent clinical event adjudication committee. |
From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
All-cause death
기간: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Time to death from any cause after randomization. |
From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
|
Aortic valve replacement
기간: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Time to first surgical or transcatheter aortic valve replacement after randomization. |
From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
|
Hospitalization for heart failure
기간: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Time to first adjudicated hospitalization for heart failure after randomization (presentation to an acute care facility requiring an overnight stay with symptoms and signs of heart failure and treatment with intravenous diuretics, vasodilators, or inotropes, mechanical fluid removal, intra-aortic balloon pump, or initiation/doubling of oral diuretics). |
From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
|
Cardiac death
기간: From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Time to adjudicated cardiovascular death, including sudden cardiac death, death due to acute myocardial infarction, heart failure or cardiogenic shock, other cardiovascular causes, or death of unknown cause without an undisputed non-cardiac cause. |
From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
|
Change from baseline in aortic valve peak velocity
기간: Baseline, 12 months, and 24 months
|
Change in peak aortic jet velocity (m/s) measured by transthoracic echocardiography. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in mean transaortic pressure gradient
기간: Baseline, 12 months, and 24 months
|
Change in mean transaortic pressure gradient (mmHg) measured by transthoracic echocardiography. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in aortic valve area
기간: Baseline, 12 months, and 24 months
|
Change in aortic valve area (cm2) calculated by the continuity equation on transthoracic echocardiography. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in dimensionless index (velocity ratio)
기간: Baseline, 12 months, and 24 months
|
Change in the dimensionless index (velocity ratio), defined as the ratio of left ventricular outflow tract to transaortic velocity (or velocity-time integral), measured by transthoracic echocardiography; unitless. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in left ventricular mass
기간: Baseline, 12 months, and 24 months
|
Change in echocardiographic left ventricular mass (g). |
Baseline, 12 months, and 24 months
|
|
Change from baseline in left ventricular global longitudinal strain
기간: Baseline, 12 months, and 24 months
|
Change in left ventricular global longitudinal strain (%) by speckle-tracking echocardiography. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in left ventricular ejection fraction
기간: Baseline, 12 months, and 24 months
|
Change in left ventricular ejection fraction (%) by transthoracic echocardiography. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in NT-proBNP
기간: Baseline, 12 months, and 24 months
|
Change in plasma N-terminal pro-B-type natriuretic peptide concentration (pg/mL). |
Baseline, 12 months, and 24 months
|
|
Annual eGFR slope
기간: From baseline through 24 months
|
Mean slope of change in estimated glomerular filtration rate (CKD-EPI equation), expressed as mL/min/1.73 m2 per year. |
From baseline through 24 months
|
|
Number of participants with at least one adverse event of special interest related to SGLT2 inhibition (safety)
기간: From first dose of study drug through 7 days after the last dose (up to approximately 25 months)
|
Number of participants experiencing one or more prespecified adverse events of special interest, reported as a single count per arm. Adverse events of special interest are: confirmed hypoglycemia (plasma glucose 70 mg/dL [3.9 mmol/L] or lower, or an event requiring assistance), urinary tract infection, genital infection, volume depletion, and acute kidney injury by KDIGO criteria. |
From first dose of study drug through 7 days after the last dose (up to approximately 25 months)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Sung-Ji Park, MD, PhD, Samsung Medical Center
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2025-07-028
- KCT0012093 (레지스트리 식별자: Clinical Research Information Service (CRIS), Republic of Korea)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Individual participant data will not be shared outside the study group because the informed consent and institutional policy do not permit external release of participant-level data. Aggregate results will be published in a peer-reviewed journal and reported to ClinicalTrials.gov.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .